ASCO Annual Meeting

Patients with high-risk classical Hodgkin lymphoma who experience a slow early response to frontline chemotherapy may benefit from the addition of pembrolizumab to COPDAC-28 consolidation.

The rate of pathologic complete responses with enfortumab vedotin was 36.4% among patients with muscle-invasive bladder.

A prostate stem cell antigen-directed CAR T-cell therapy agent showed preliminary efficacy in patients with metastatic castration-resistant prostate cancer.

Patients with advanced urothelial carcinoma who received avelumab reported any-grade treatment-related adverse events at a rate of 78.2%.

Jaktinib is a novel JAK and AVCR1 inhibitor that showed activity in patients with myelofibrosis who were intolerant to or progressed on ruxolitinib.

For patients with myelofibrosis receiving pacritinib, spleen volume reduction was associated with improved overall survival.

Patients with breast and gastrointestinal cancers reported fewer hand-foot syndrome events following treatment with topical diclofenac gel.

The phase 1/2 TRANSCEND CLL 004 trial met its primary end point by demonstrating that lisocabtagene maraleucel elicited responses in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.

Talazoparib reduced the risk of progression or death by 55% in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations.

Second-line treatment with CDK4/6 inhibition was associated with fewer toxicities and drug costs than frontline CDK4/6 inhibitor treatment—although progression-free survival and overall survival outcomes were similar.

The rates of treatment discontinuation were higher with enzalutamide and apalutamide than with darolutamide for patients with non-metastatic castration resistant prostate cancer.

Frontline chemoimmunotherapy was associated with improved median overall survival, compared with chemotherapy alone, in patients with advanced non–small cell lung cancer.

Maintenance bevacizumab plus durvalumab and olaparib improved progression-free survival in patients with HRD-negative advanced ovarian cancer.

The median progression-free survival with atezolizumab to cabozantinib was 10.6 vs 10.8 months with cabozantinib alone.

Patients with relapsed/refractory multiple myeloma treated with elranatamab following any prior BCMA-directed therapy achieved an overall response rate of 46%.

Omitting radiotherapy did not compromise overall survival rates for patients with primary mediastinal B-cell lymphoma.

Patients with ESR1 mutations who received 12 months or more of prior treatment with a CDK4/6 inhibitor achieved a median progression free survival of 8.61 months with elacestrant compared with 1.91 months for those given standard therapy.

Patients with HER2-positive, metastatic colorectal cancer derived clinical benefit from a 5.4 mg/kg dose of trastuzumab deruxtecan.

Enfortumab vedotin plus pembrolizumab elicited durable responses in patients with locally advanced or metastatic urothelial carcinoma who were ineligible for cisplatin.

According to investigators, digitized cognitive behavioral stress management may help clinicians offer more comprehensive cancer care.

Sacituzumab govitecan improved overall survival vs treatment of physician’s choice in pretreated, endocrine-resistant, hormone receptor–positive, HER2-negative metastatic breast cancer.

Ciltacabtagene autoleucel improved progression-free survival vs pomalidomide, bortezomib, and dexamethasone or daratumumab, pomalidomide, and dexamethasone in patients with lenalidomide-refractory multiple myeloma.

Adjuvant mRNA-4157, in combination with pembrolizumab, improved recurrence-free survival, and distant metastasis-free survival, for patients with high-risk melanoma.

Phase 2 findings show that adding a tyrosine kinase inhibitor to dual immunotherapy curbed disease progression in patients with metastatic soft tissue sarcoma.

Numerical, but not statistically significant, improvements in survival were observed in patients with TKI-resistant, EGFR-mutated, metastatic nonsquamous non–small cell lung cancer who received pembrolizumab to pemetrexed and platinum-based chemotherapy.

Sintilimab plus chemoradiotherapy was associated with better event-free survival rates in locally advanced nasopharyngeal carcinoma than chemoradiotherapy alone.

A 5-year analysis of the phase 3 KEYNOTE-426 trial showed continued benefit with pembrolizumab plus axitinib for patients with advanced treatment-naïve clear cell renal cell carcinoma.

Axicabtagene ciloleucel delivered superior overall survival compared with standard of care in patients with early relapsed or refractory large B-cell lymphoma.

Patients with pretreated FGFR2/3-altered metastatic urothelial cancer derived a significant survival benefit with erdafitinib.

In the phase 2 DESTINY-PanTumor02 trial, trastuzumab deruxtecan elicited clinical activity across a range of HER2 expressing solid tumors.